HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Elizabeth Arden 2007 results

This article was originally published in The Rose Sheet

Executive Summary

Firm records $1.128 bil. in sales for FY 2007, up 18% from 2006. Net fourth-quarter sales increased 28% to $242.7 mil., driven by a 51% increase in firm's U.S. mass business and a 27% increase in its U.S. Elizabeth Arden Department store business. International business increased 12% during the Q4, with strong performances from Britney Spears fragrances, according to Arden. Total fragrance sales in North America soared 40% in Q4 and 23% for the full year, with gains primarily in the mass channel. North American fragrance store and department store business was down 6% in 2007, Arden notes. "The key accomplishment for fiscal 2007 year was ... the Elizabeth Arden brand itself - it grew16 percent," Chairman, President and CEO E. Scott Beattie remarked during Aug. 16 call. The Prevage brand advanced more than 45% in 2007, with especially strong growth in travel retail in Asia. Arden plans to launch M by Mariah Carey worldwide in early September, followed by Britney Spears Believe later that month...

You may also be interested in...



Novartis Pharma President Marie-France Tschudin On Inclisiran, Launches And More

Tschudin talked to Scrip about taking over as Novartis Pharmaceuticals president, why inclisiran is different from marketed PCSK9 inhibitors and prioritizing investment behind multiple new launches.

Celebrity Takes Role In US FDA Study Of Rx Drug Endorsements

Agency hasn't named the celebrity that will participate in the study on the impact that celebrity and non-celebrity endorsements have on consumer perceptions about Rx drugs.

Vyondys 53 Clinical Development Timeline

Chronicle of the development and review of Sarepta’s golodirsen for treatment of Duchenne muscular dystrophy patients with a genetic mutation amenable to exon 53 skipping.

UsernamePublicRestriction

Register

RS014915

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel